Mauna Kea Technologies SA (ALMKT) – aksjekurser og nyheter

ALMKT:EPA

Mauna Kea Technologies SA

0,092 €

0,00%

(0,00) 1 D

13. nov., 17:35:01 GMT+1 · EUR

Alle symboler

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for ALMKT …

Åpne

0,09 €

Høy

0,10 €

Lav

0,09 €

Markedsverdi

18,14 mill.

Snittvolum

541,14k

Volum

75,16k

P/E-forhold

0,79

52 u høy

0,23 €

52 u lav

0,07 €

EPS

0,12 €

Utestående aksjer

195,26 mill.

Antall ansatte

Åpne

0,09 €

Høy

0,10 €

Lav

0,09 €

Markedsverdi

18,14 mill.

Snittvolum

541,14k

Volum

75,16k

P/E-forhold

0,79

52 u høy

0,23 €

52 u lav

0,07 €

EPS

0,12 €

Utestående aksjer

195,26 mill.

Antall ansatte

Relaterte aksjer

Nyhetssaker

Fra nettkilder og nyhetspartnere

24/7 Wall St.

for 31 minutter siden

Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500

BigGo Finance

for 2 timer siden

Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks

The Motley Fool

for 2 timer siden

Tesla Is Down 13% in 2026 While the S&P 500 Is Up. Here’s the 1 Catalyst Left This Year That Could Flip That.

StoneX

for 2 døgn siden

S&P 500, Nasdaq 100 Claw Back But NVDA Cloud Looms Overhead

Profil

Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts. The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues. Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time. Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia

Om Mauna Kea Technologies SA

Administrerende direktørSacha Loiseau

Ansatte56

Grunnlagt2000

Hovedkontor-

SektorHealth Care

Bransje-

Nettstedmaunakeatech.com

Alle verdier i EUR	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	2,44 mill.	2,44 mill.	1,75 mill.	1,75 mill.
Varekostnad	528,00k	528,00k	494,50k	494,50k
Direkte driftskostnader	528,00k	528,00k	494,50k	494,50k
Utgifter til forskning og utvikling	861,00k	861,00k	796,00k	796,00k
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	1,89 mill.	1,89 mill.	2,13 mill.	2,13 mill.
Driftskostnader	3,11 mill.	3,11 mill.	3,33 mill.	3,33 mill.
Totale driftskostnader	3,64 mill.	3,64 mill.	3,83 mill.	3,83 mill.
Driftsinntekter	−1,20 mill.	−1,20 mill.	−2,08 mill.	−2,08 mill.
Andre ikke-operasjonelle inntekter	10,84 mill.	10,84 mill.	−236,00k	−236,00k
EBT inkludert uvanlige elementer	7,69 mill.	7,69 mill.	−2,41 mill.	−2,41 mill.
EBT uten uvanlige elementer	8,06 mill.	8,06 mill.	−2,41 mill.	−2,41 mill.
Kostnad for inntektsskatt	−35,50k	−35,50k	-	-
Faktisk avgiftssats	−0,46 %	−0,46 %	-	-
Andre driftskostnader	92,00k	92,00k	95,00k	95,00k
Nettoinntekt	7,72 mill.	7,72 mill.	−2,41 mill.	−2,41 mill.
Netto fortjenestemargin	316,50 %	316,50 %	−137,65 %	−137,65 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	-	-	-	-
Rentekostnader	−490,50k	−490,50k	−25,50k	−25,50k
Netto rentekostnader	−490,50k	−490,50k	−25,50k	−25,50k
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−1,11 mill.	−1,11 mill.	−2,04 mill.	−2,04 mill.
Gevinst eller tap ved salg av eiendeler	281,00k	281,00k	-	-

Spør om hva som helst